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Monocytes are the likely candidate 'stromal' cell in G-CSF-mobilized peripheral blood
In a recent Bone Marrow Transplantation report, Fernández et al 1 concluded that stromal cells can be detected in peripheral blood progenitor cell (PBPC) collections from breast cancer patients. They reported that low density cells from PBPC express a variety of stromal markers and are negative for the myeloid markers CD34, CD45 and CD14. From these results they concluded that the cells are stromal cells that have been released from the marrow after cytokine mobilization. Their data, however, do not convincingly support their conclusions and we suspect that they are growing a population of cells we have previously reported as being osteoclasts and their progenitors. 2 First, the figures showing immunostaining are not convincing. No isotype-matched controls are given for comparison, and the staining is weak and diffuse raising the possibility that it is due to background fluorescence or nonspecific binding of the antibodies. When a study relies heavily on phenotypical characterization, as does the report by Fernández et al, 1 isotype-matched nonbinding antibodies are necessary to show specific binding. In addition, such studies should include positive and negative control populations, to ensure that results obtained were true positives or negatives, and were not merely the outcome of artifacts introduced due to experimental techniques. For these reasons, all immunostaining data provided by Fernández and colleagues are, in our opinion, questionable regarding their accuracy.
In our study, 2 we reported the growth of pre-osteoclasts and osteoclasts from PBPC when cultures were initiated at high density. We fully characterized these cells as being osteoclasts by their expression of tartrate-resistant acid phosphatase, the absence of CD14 expression, the presence of calcitonin receptors and their ability to resorb bone. The round and 'fibroblast-like' cells described by Fernández and colleagues are morphologically identical to cell types we observed as being pre-osteoclasts. The failure of Fernández et al to observe the formation of multinucleated osteoclasts is possibly due to the fact that their cultures were initiated at a low density (1.04 ϫ , detection of osteoclasts was rare. The density used by Fernández et al 1 was at the lowest limit that we reported necessary for formation of aggregates that preceded osteoclast development, hence it is possible that the pre-osteoclast aggregates did not form well at this density in their culture conditions. In addition, the different methods of establishment of the cultures may also have affected the growth of the osteoclasts: we used buffy coat preparations in comparison to post-Ficoll preparations used by Fernández et al, this would undoubtedly alter the composition of the cellular components of the product and may have removed accessory cells, such as T lymphocytes, that we believe are required to provide necessary factors for the growth of the osteoclasts. Fernández and colleagues also used a higher concentration of fetal calf serum (20% vs 10% that we used) in their medium, and this may have inhibited the growth of the osteoclasts: while we did not test 20% serum in our alpha minimum essential medium, we did test the growth of the osteoclasts in medium 199 containing 20% FCS, as well as long-term culture medium that contains both horse and fetal calf serum, and, as reported in our paper, these media did not support the growth of osteoclasts. 2 It may be possible, therefore, that higher concentrations of serum are inhibitory to the formation of osteoclasts from their precursors.
Although our report was based on observations made with PBPC from normal donors, we have also observed the same results with PBPC from mobilized cancer patients, including breast cancer patients (Purton and Torok-Storb, unpublished observations). We believe that one factor that influences the formation of osteoclasts from PBPC is the increased number of circulating monocytes, from which osteoclasts are derived, that are detectable in this product. 3, 4 In addition, Fukuda et al 4 reported a large increase in monocytic progenitors in PBPC derived from patients who had undergone chemotherapy prior to mobilization with G-CSF, hence it is not likely that the PBPC product used by Fernán-dez and colleagues was very different to that utilized in our studies. Furthermore, Pierelli et al 5 have reported the growth of osteoclasts from PBPC obtained from mobilized ovarian cancer patients, albeit under different culture conditions to those reported by us and Fernández and colleagues.
The cells reported by Fernández et al, 1 while lacking expression of the mature macrophage marker, CD14, did express markers of more immature monocytes, including ␣-naphthyl butyrate esterase and acid phosphatase. The enzyme, ␣-naphthyl butyrate esterase, is an enzyme of monocytes, 6 and to our knowledge it is not expressed by stromal cells. In addition, these markers are all characteristic of osteoclast precursors, which are derived from monocytic cells, and specifically defined as being CD14 negative, but positive for ␣-naphthyl butyrate esterase and tartrateresistant acid phosphatase expression. 7, 8 While osteoclasts have been reported to be CD45 positive, 9 and the cells reported by Fernández et al were reported to be negative for this marker, Fernández et al did not show any data for this staining and have not stated if positive and negative control populations were used alongside the test population to determine that the staining did work and that the 'negative result' was not merely due to experimental error. Given the unconvincing immunostaining in Figure 2 of their paper, we would question this result. Furthermore, other markers expressed by the cells reported in Fernández' study, including fibronectin and ICAM-1, have also been shown to be expressed by osteoclasts, hence, even if the immunostaining was correctly performed, the data are not conclusive of the cells being stromal cells. 9, 10 Bone marrow stromal cells, by classical definition, are composed of mesenchymal cells: reticular cells, adipocytes and endothelial cells; and hematopoietic cells; monocyte/macrophages and lymphocytes. [11] [12] [13] The latter are better defined as 'accessory cells' due to their hematopoietic nature. Mesenchymal cells usually grow in an overlapping or cell-cell contact pattern as shown in Figure 1 of the report by Wilkins and Jones, 14 not in a dispersed, contact-inhibited type formation shown in the report by Fernández and colleagues. 1 In fact, the cells described by the latter investigators are more in accordance with a monocyte/macrophage population described by Wilkins and Jones 14 as being 'elongated and flattened, often with several short dendritic processes . . . Cultures at 2 weeks were virtually devoid of this second type of macrophage, but by 4 weeks they were numerous' (p 760).
The antibodies SH2 and SH3 were raised against marrow-derived mesenchymal cells that were able to be culture-expanded, passaged and functionally were capable of forming bone. 15 These criteria have not been demonstrated to be fulfilled by the 'stromal' cells described in the report by Fernández and colleagues. 1 In addition, in the report describing the SH2 and SH3 antibodies, 15 we also read with interest that 'in contrast to the positive staining of the three antibodies to the cell surface of the culture-expanded mesenchymal cells, practically no cells are reactive when the antibodies are assayed against cell suspensions derived from whole marrow or the low-density fraction of marrow generated by Percoll gradient fractionation . . . Positively stained cells are observed at very low frequency in both samples, and may indicate the presence of a few mesenchymal cells; however, the exact identity of the positively staining cells has not been definitely shown, since similar positively stained cells are infrequently seen in samples incubated with the FITC-labeled second antibody in the absence of primary antibody' (p 72). Given that the profiles for SH2 and SH3 offered by Fernández and colleagues 1 do not have proper controls, as only unstained controls are given in comparison (Figure 3) , it may be possible that the population they are describing correlates to these unidentified, nonspecifically binding cells. The morphology of the cells described by Fernández and colleagues 1 is also quite distinct from that of the mesenchymal cells shown in Figure  1 of the initial report by Haynesworth et al, 15 and in our opinion, despite the different magnifications of the micrographs published by the authors, the 'fibroblast-like' cells described by Fernández et al appear to be quite similar to those shown in the macrophage population ( Figure 3 ) described by Wilkins and Jones. 14 In conclusion, we believe that the cells reported by Fernández et al 1 as being stromal cells are, in fact, monocytic cells, which are capable of maturing into osteoclasts or macrophages, depending upon the culture conditions used.
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